We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Charlotte
Coles
Breast cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2006 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/17051947 protocol2007 Other publications in https://doi.org/10.1016/j.clon.2007.01.320 forward planning analysis2011 Other publications in https://www.ncbi.nlm.nih.gov/pubmed/20605349 Trial planning2014 Interim results article in https://www.ncbi.nlm.nih.gov/pubmed/25642565 Results of observational sub-study comparing image-guided radiotherapy and standard imaging.2015 Interim results article in https://www.ncbi.nlm.nih.gov/pubmed/26492402 clinical impact results2019 Abstract results in https://doi.org/10.1158/1538-7445.SABCS18-GS4-05 3-year adverse event results presented at San Antonio Breast Cancer Symposium (added 30/12/2022)2021 Abstract results in https://www.estro.org/Congresses/ESTRO-2021/499/profferedpapers16-late-breakingabstracts/3418/importhightrial-doseescalatedsimultaneousintegrate Presented at ESTRO (added 30/12/2022)2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37302395/ (added 12/06/2023)
You can take part if:
Current inclusion criteria as of 26/02/2019:
1. Operable unilateral breast cancer (T1-3, pN0- pN3a, M0 at presentation)
2. Breast conserving surgery
3. Age greater than or equal to 18 years
4. Histological confirmation of invasive carcinoma
5. Complete microscopic resection
6. Patient requires a tumour bed boost plus whole breast radiotherapy for inclusion within the trial
7. Written informed consent and avai
You may not be able to take part if:
Current exclusion criteria as of 26/02/2019:1. Past history of malignancy except:1.1. Basal cell skin cancer and CIN cervix uteri or1.2. Non breast malignancy allowed if treated with curative intent and at least 5 years disease free2. Mastectomy3. Concomitant chemotherapy (primary or sequential chemotherapy allowed).4. Presence of ipsilateral breast implant
Previous exclusion criteria:1. Previous malignancy (other than non-melanomatous skin cancer and Carcinoma In Situ [CIS] of the cervix)2. Mastectomy3. Concomitant chemotherapy (sequential chemotherapy allowed)4. Radiotherapy prescription includes posterior axillary boost field
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.
Prof
Charlotte
Coles
The study is sponsored by Institute of Cancer Research (UK) and funded by Cancer Research UK (UK) (ref: C1491/A16831).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 2254
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
